- Home
- PEW vs MNOV Comparison
PEW vs MNOV Comparison
Compare PEW & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEW | MNOV |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 67.9M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | PEW | MNOV |
|---|---|---|
| Price | $2.50 | $1.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.75 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 895.6K | 37.0K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $5.25 | N/A |
| Revenue Next Year | $7.96 | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $2.25 | $1.17 |
| 52 Week High | $7.19 | $1.96 |
Technical Indicators
Market Signals| Indicator | PEW | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 39.58 |
| Support Level | $2.25 | $1.24 |
| Resistance Level | $3.22 | $1.46 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 22.91 | 6.67 |
Price Performance
Historical ComparisonAbout PEW GrabAGun Digital Holdings Inc.
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.